ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of Company Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total transaction of $36,795.00. Following the completion of the transaction, the vice president directly owned 73,424 shares in the company, valued at approximately $5,403,272.16. This represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $70.79, for a total transaction of $35,395.00.
• On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP traded down $2.75 during trading hours on Tuesday, hitting $70.84. 331,803 shares of the stock were exchanged, compared to its average volume of 444,460. ANI Pharmaceuticals, Inc. has a one year low of $69.58 and a one year high of $97.00. The company’s 50 day moving average is $74.11 and its 200 day moving average is $78.04. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a market capitalization of $1.63 billion, a P/E ratio of 15.27, a P/E/G ratio of 2.37 and a beta of 0.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter last year, the firm posted $1.80 EPS. The business’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE acquired a new position in ANI Pharmaceuticals in the second quarter worth about $15,154,000. NFJ Investment Group LLC bought a new position in ANI Pharmaceuticals during the second quarter worth about $2,766,000. Walleye Capital LLC acquired a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $8,784,000. Jupiter Topco LLC acquired a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $6,597,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $1,449,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on ANIP shares. Guggenheim lowered their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Oppenheimer started coverage on ANI Pharmaceuticals in a report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price target for the company. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group reduced their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Hold” and an average target price of $99.60.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.